Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
28,000
NCT04847102
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Phase: Phase 3
Role: Collaborator
Start: Jul 22, 2021
Completion: May 30, 2023